angelMD Completes Investment in Bleeding Detection Medical Device Company

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

angelMD announced the closure of a new syndicate investment in Saranas, a promising new medical device startup. Dan Parsley, angelMD’s SVP of Corporate Development, served as the syndicate leader for this first investment in Saranas by angelMD members, and this angelMD syndicate is part of Saranas’ recently announced $4 million Series B financing round.

Saranas is working to create a way to quickly and accurately diagnose complications in vascular access procedures, while lowering patient and provider costs. Every year, twenty million American patients undergo these procedures to provide longer term access for intravenous (IV) medical treatments, and as many as a million of these patients experience life-threatening complications as a result of an inability to quickly account for problems like internal bleeding. These issues cost patients and providers a collective $8.4B dollars each year.

Parsley stated, “With the growth of value-based insurance reimbursements combined with the increasing popularity of intravenous heart procedures, patients and doctors are demanding better procedural outcomes. This innovative real-time bleeding detection device by Dr. Razavi is designed to be integrated directly into common catheter sheaths, and I’m confident many existing cardiac medical device companies will see the immediate value of this technology.”

Saranas is angelMD’s first investment of technology originating from the prestigious Texas Heart Institute at the Texas Medical Center.

Saranas CEO Zaffer Syed said, “We are thrilled to be adding angelMD to our investor base. With access to physician investors, angelMD brings a strong track record of adding real value to its portfolio companies. This Series B financing reflects a deep commitment to Saranas’ innovative approach for enhancing patient outcomes during vascular access procedures.”

Parsley concluded, “Saranas has the management team and an experienced board that will be able to see this innovative technology through FDA clearance, and we are excited to help this company grow and become an industry leader.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles